The serum level of resistin and cytokines in patients with diabetes mellitus associated with arterial hypertension depending on the compensation level of diabetes mellitus
Pdf (Українська)

Keywords

resistin, interleukin‑2, interleukin‑6, tumor-necrosis factor α, type 2 diabetes, arterial hypertension

How to Cite

Urbanovych, A., & Mankovsky, B. (2016). The serum level of resistin and cytokines in patients with diabetes mellitus associated with arterial hypertension depending on the compensation level of diabetes mellitus. Endokrynologia, 21(1), 16-20. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/111

Abstract

Aim.The objective of the present study is to investigate the changes in the resistin and cytokines level, including IL‑2, IL‑6 and TNF-α, in the serum of patients with different level of compensation of diabetes mellitus (DM) associated with arterial hypertension (AH); and to explore the possible relationship between the aforementioned adypokin and cytokines. Methods. The study involved 137 (72 female and 65 male) patients with DM associated with AH (I-II level) and non-associated with AH. The level of resistin, IL‑2, IL‑6, TNF-α in the blood serum were determined by ELISA. Results. The significant increase of resistin level in patients with DM and poor level of AH compensation were found. Moreover, growth of
IL‑6 level in the group with good and satisfactory compensated DM and increase of TNF-α level in the group with poorly compensated DM connected with AH were also noticed. The positive correlation between resistin level and IL‑2 and TNF-α level were found in both groups with poor compensation of DM (associated and nonassociated with AH), with greater level in the group associated with AH. Conclusions. Resistin level in the blood serum increases with worsening of compensation of DM associated with AH. Positive correlation between level of resistin, IL‑2 and TNF-α in patients with poorly compensated DM may indicate mutual strengthening of these factors in development and progression of  ecompensation
of DM associated with AH.

Pdf (Українська)

References

1. Журавльова Л.В., Пивоваров О.В. Фактори ризику та прогнозування розвитку поєднаної патології цукрового діабету 2-го типу у хворих на артеріальну гіпертензію // Мистецтво лікування. — 2014. — № 9-10. — С. 115-116. (Zhuravlova L.V., Pyvovarov O.V. Risk factors and prediction of comorbidity of type 2 diabetes mellitus in patients with arterial hypertension // Mystetstvo likuvannia. — 2014. — № 9-10. — P. 115-116).
2. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.R., Ahima R.S., Lazar M.A. The hormone resistin links obesity to diabetes // Nature. — 2001. — Vol. 409,
№ 6818. — P. 307-312.
3. Rajala M.W., Qi Y., Patel H.R., Takahashi N., Banerjee R., Pajvani U.B., Sinha M.K., Gingerich R.L., Scherer P.E., Ahima R.S. Regulation of resistin expression and circulating
levels in obesity, diabetes, and fasting // Diabetes. — 2004. — Vol. 53, № 7. — Р. 1671-1679.
4. Shuldier A., Yang R., Gong D. — W. Resistin, obesity and insulin resistance // N. Engl. J. Med. — 2001. Vol. 345. — P. 1345-1346.
5. Barnes K.M., Miner J.L. Role of resistin in insulin sensitivity in rodents and humans // Curr. Protein Pept. Sci. — 2009. — Vol.10, № 1. — P. 96-107.
6. Pischon T. Use of obesity biomarkers in cardiovascular epidemiology // Dis. Markers. — 2009. — Vol. 26, № 5-6. — P. 247-263.
7. Mattu H.S., Randeva H.S. Role of adipokines in cardiovascular disease // J. Endocrinol. — 2013. — Vol. 216. — P. 17-36.
8. Дранник Г.Н. Клиническая иммунология и аллергология. — К., 2010. — 547 с. (Drannik G.N. Clinical immunology and allergology. — K., 2010. — 547 p.).

Downloads

Download data is not yet available.